These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10763143)

  • 21. An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays.
    Chapman JW; Mobbs BG; McCready DR; Lickley HL; Trudeau ME; Hanna W; Kahn HJ; Sawka CA; Fish EB; Pritchard KI
    J Steroid Biochem Mol Biol; 1996 Mar; 57(5-6):323-8. PubMed ID: 8639468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
    Lundgren S; Søreide JA; Lea OA
    Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
    Rhodes A; Jasani B; Balaton AJ; Miller KD
    J Clin Pathol; 2000 Apr; 53(4):292-301. PubMed ID: 10823126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
    Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
    Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer.
    Robertson JF; Cannon PM; Nicholson RI; Blamey RW
    Int J Biol Markers; 1996; 11(1):29-35. PubMed ID: 8740639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen and progesterone receptor assays, by the EIA method (Abbott), of low-speed supernates of breast-cancer homogenates.
    Hähnel R; Avenell MH; Hähnel E
    Clin Chem; 1989 Nov; 35(11):2226-7. PubMed ID: 2684449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
    Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC; ;
    Arch Pathol Lab Med; 2010 Jul; 134(7):e48-72. PubMed ID: 20586616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical and methodological considerations in the quantification of estrogen and progesterone receptors using monoclonal antibodies in breast cancer].
    Navarro MA; Huguet J; Valero J; Samaniego JM; Rosel P; Sirvent JJ
    Med Clin (Barc); 1991 Jun; 97(2):41-4. PubMed ID: 1895780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunocytochemical localization of estrogen and progesterone receptors (ER & PgR) in breast cancer.
    Fukushima H; Matsuda M; Kawakami H; Kudo A; Kuroki Y; Sakurai M; Shohji T; Nagashima Y; Asami M; Hanaoka T
    Okajimas Folia Anat Jpn; 1995 Mar; 71(6):365-70. PubMed ID: 7739846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytological evaluation of biological prognostic markers from primary breast carcinomas.
    Makris A; Allred DC; Powles TJ; Dowsett M; Fernando IN; Trott PA; Ashley SE; Ormerod MG; Titley JC; Osborne CK
    Breast Cancer Res Treat; 1997 May; 44(1):65-74. PubMed ID: 9164679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Receptor status (ER and PgR) determined with histochemical and biochemical methods in breast carcinoma].
    Simone G; Paradiso A; Cirillo R; Mangia A; Rella G; Wiesel S; Petroni S; De Benedictis G; De Lena M
    Pathologica; 1991; 83(1086):449-59. PubMed ID: 1724316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents.
    Gotteland M; May E; May-Levin F; Contesso G; Delarue JC; Mouriesse H
    Cancer; 1994 Aug; 74(3):864-71. PubMed ID: 7913659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for bimodal distribution of breast carcinoma ER and PgR values quantitated by enzyme immunoassay.
    Mobbs BG; Chapman JA; Sutherland DJ; Ryan E; Tustanoff ER; Ooi TC; Murthy PV
    Eur J Cancer; 1993; 29A(9):1293-7. PubMed ID: 8343271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases.
    Zafrani B; Aubriot MH; Mouret E; De Crémoux P; De Rycke Y; Nicolas A; Boudou E; Vincent-Salomon A; Magdelénat H; Sastre-Garau X
    Histopathology; 2000 Dec; 37(6):536-45. PubMed ID: 11122436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: evaluation of discordant findings.
    Stierer M; Rosen H; Weber R; Hanak H; Auerbach L; Spona J; Tüchler H
    Breast Cancer Res Treat; 1998 Jul; 50(2):125-34. PubMed ID: 9822217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
    Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
    Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
    Bardou VJ; Arpino G; Elledge RM; Osborne CK; Clark GM
    J Clin Oncol; 2003 May; 21(10):1973-9. PubMed ID: 12743151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.